Abstract
The treatment of an aqueous acetonitrile solution of chloroplatinic acid hydrate H
2
PtCl
6
.xH
2
O and pyridine-2-carbaldehyde-oxime (paOH) in the presence of potassium thiocyanate at room temperature (25°) led to the formation of a new Pt(IV) complex with the formula
[Pt(SCN)
2
(paO)
2
], (1).
Complex
1
was fully characterized by FT-IR, UV-vis and NMR spectroscopic techniques as well as elemental analysis. The crystallographic structure of complex
1
was obtained by single-crystal X-ray diffraction. The structure of complex
1
consists of a distorted octahedral geometrical environment around the platinum center in which the coordination sites are occupied by two terminal thiocyanate ligands in
trans
arrangement and two bidentate paO ligands through four nitrogen atoms. In addition, the in vitro evaluation of the cytotoxicity of platinum complex
1
against four different cancer cell lines was performed. The IC
50
values for colon (HCT116), liver (HepG2), breast (MCF-7) and erythroid (JK-1) treated with complex
1
are 19 ± 6, 21 ± 5, 22 ± 6, and 13 ± 3 μM, respectively. In HCT116 cells treated with the IC50 dose of our title compound, apoptosis and necrosis were increased by 34% and 27.8%, respectively. Cells halted in the proliferative phase (S phase) to 21.7 % and 29.8% in HCT116 and HepG2 cells treated with complex
1
have anti-proliferative actions. Furthermore, the catalytic activity of synthesized complex
1
was examined in the oxidation reaction of benzyl alcohols in the presence of an oxidant. Finally, the luminescence behavior of complex
1
was investigated.